Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTOPS: multiTAA-specific T cells in pancreatic cancer
NCT03192462Phase 2Completed
- Sponsor
- Baylor College of Medicine
- Start
- Jan 2018
- Primary completion
- Jun 2020
- Countries
- 1
01
Overview
Phase 2, open-label trial of multiTAA specific T cells in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by Baylor College of Medicine. Primary endpoints: Number of Patients With Treatment Related Serious Adverse Events at 7 months and Number of Patients Who Received 6 Infusions of multiTAA-specific T Cells at 6 months. Started Jan 2018; status: completed.
02
Drugs
multiTAA specific T cells
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03192462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03192462.